

## **Supplemental Material to:**


**Melissa Brunckhorst, Dimitry lerner, Shaomeng Wang and  
Qin Yu**

**AT-406, an orally active antagonist of multiple inhibitor of  
apoptosis proteins, inhibits progression of human ovarian  
cancer**

**Cancer Biology & Therapy 2012; 13(9)  
<http://dx.doi.org/10.4161/cbt.20563>**

**<http://www.landesbioscience.com/journals/cbt/article/20563/>**


**Supplemental Figure 1. Single agent effects of AT-406 in the AT-406 sensitive human ovarian cancer cells.** AT-406 sensitive human ovarian cancer cell lines were treated with additional lower doses of AT-406 for 48 hours and the cell viability assays were performed using the Cell Glo-Titer assay (Promega).



Brunckhorst\_Supplemental Figure 1


**Supplemental Figure 2. Establishment of the orthotopic ovarian cancer mouse model.**

**A**, the Protocol for generation of an orthotopic OVCAR-3ip ovarian cancer model in immunocompromised mice. Photographs are representative of mice approximately 6 weeks following intraperitoneal injection of  $5 \times 10^6$  OVCAR-3ip cells. **B**, Representative images of hemotoxylin and eosin (H&E) stained tumor sections derived from disseminated ovarian cancer cells associating with the peritoneum, liver, and mesentery of the experimental mice.



**Brunckhorst\_Supplemental Figure 2**

**Supplemental Figure 3. AT-406 treatment reduces cIAP1 protein levels in human ovarian cancer cells.** A-B, human ovarian cancer cells, OVCAR-3, IGROV1, OVCAR-3ip, and SKOV-3, were treated with the indicated amounts of AT-406 for 48 hours. The cells were harvested at varying time points as indicated in the panels and the proteins were probed for cIAP1. Actin was used as a loading control.



Brunckhorst\_Supplemental Fig 3